Advanced Cell Technology’s Chief Scientific Officer Dr. Robert Lanza Named One of TIME Magazine’s 100 Most Influential Pe...
April 24 2014 - 10:41AM
Business Wire
Dr. Lanza and the other TIME 100 will be
honored at a Gala Event on Tuesday April 29, 2014
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in
the field of regenerative medicine, announced today that the
company’s Chief Scientific Officer, Robert Lanza, MD, has been
selected for the 2014 TIME 100 annual list of the hundred
most influential people in the world. The TIME 100 issue,
containing the full list hits newsstands on Friday, April 25.
A gala honoring this years’ TIME 100 will be held
on Tuesday, April 29, 2014 at Jazz at Lincoln Center in New
York City. The event brings together the world’s leading figures in
politics, technology, science, philanthropy, media, business and
entertainment and attracts worldwide media coverage. Last year’s
gala featured a performance by Christina Aguilera and remarks by
Vice President Joe Biden; the previous year’s keynote speaker was
Secretary of State Hillary Clinton, with performances by Rihanna
and Stephen Colbert. Past guests have included President Bill
Clinton, Justin Timberlake, Oprah Winfrey, Carlos Slim, Amy
Poehler, Jeremy Lin, Gabrielle Giffords, Steven Spielberg and Lena
Dunham as well as activists and thinkers who are making a
difference in the world, whether fighting for human rights or
seeking a cure for cancer.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc., (ACT) is a Marlborough,
Mass.-based biotechnology company focused on the development and
commercialization of human embryonic stem cell (hESC) and adult
stem cell technology. The company’s most advanced products are in
clinical trials for the treatment of dry age-related macular
degeneration and Stargardt’s macular degeneration. These cell
therapies are also clinical trial candidates for the treatment of
myopic macular degeneration. ACT’s preclinical programs involve
cell therapies for the treatment of other ocular disorders and for
diseases outside the field of ophthalmology, including autoimmune,
inflammatory and wound healing-related disorders. The company’s
intellectual property portfolio includes pluripotent stem cell
platforms – hESC and induced pluripotent stem cell (iPSC) – and
other cell therapy research programs. For more information, visit
www.advancedcell.com or connect with the Company on Facebook,
Twitter, LinkedIn, Google+ and YouTube.
Investors:CEOcast, Inc.Robert Woods, 212-732-4300orPress:Russo
PartnersDavid Schull, 212-845-4271